Janssen Presents P-I/II (MGT009) and P-I Study Results of Two Gene Therapy Programs for X-Linked Retinitis Pigmentosa and Dry AMD at AAO 2022
Shots:
- The P-I/II (MGT009) dose-escalation study evaluated botaretigene sparoparvovec in 49 patients aged ≥5yrs. with XLRP associated with RPGR gene
- The results showed an acceptable safety profile & efficacy, improvement in retinal sensitivity, visual function & functional vision, and improvement in walk time @26wk. b/w the treated eyes in low & intermediate dose cohorts & untreated eyes in the randomized concurrent control arm at low illumination levels. The safety profile was consistent with prior reports, AE was anticipated & manageable with no dose-limiting events
- The company also presented the results from the P-I study of 3 doses of JNJ-1887 for dry AMD with GA which met the 1EPs of safety over 2yr. follow-up period & continual decline in lesion growth over 6mos.
Ref: Janssen | Image: Janssen
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
